These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 24582273

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Chaturvedi S, Zivin J, Breazna A, Amarenco P, Callahan A, Goldstein LB, Hennerici M, Sillesen H, Rudolph A, Welch MA, SPARCL Investigators.
    Neurology; 2009 Feb 24; 72(8):688-94. PubMed ID: 18768917
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
    Goldstein LB, Amarenco P, Szarek M, Callahan A, Hennerici M, Sillesen H, Zivin JA, Welch KM, SPARCL Investigators.
    Neurology; 2008 Jun 10; 70(24 Pt 2):2364-70. PubMed ID: 18077795
    [Abstract] [Full Text] [Related]

  • 6. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P, Goldstein LB, Sillesen H, Benavente O, Zweifler RM, Callahan A, Hennerici MG, Zivin JA, Welch KM, Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators.
    Stroke; 2010 Mar 10; 41(3):426-30. PubMed ID: 20110538
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
    Kongnakorn T, Ward A, Roberts CS, O'Brien JA, Proskorovsky I, Caro JJ.
    Value Health; 2009 Sep 10; 12(6):880-7. PubMed ID: 19490555
    [Abstract] [Full Text] [Related]

  • 9. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, Vicente V, Lip GY.
    J Am Coll Cardiol; 2013 Dec 10; 62(23):2199-204. PubMed ID: 24055744
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
    Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C, German Diabetes and Dialysis Study Investigators.
    Am J Kidney Dis; 2009 Nov 10; 54(5):902-11. PubMed ID: 19781835
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
    Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, Sattar N, ASCOT Investigators.
    J Am Coll Cardiol; 2013 Aug 20; 62(8):717-29. PubMed ID: 23948514
    [Abstract] [Full Text] [Related]

  • 14. Risk of vascular events after nondisabling small and large vessel cerebral ischemia.
    Achterberg S, Pruissen DM, Kappelle LJ, Algra A, SMART Study Group.
    Cerebrovasc Dis; 2013 Aug 20; 36(3):190-5. PubMed ID: 24135529
    [Abstract] [Full Text] [Related]

  • 15. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T, Matsuyama Y, Iimuro S, Umegaki H, Sakurai T, Araki A, Ohashi Y, Ito H, Japanese Elderly Diabetes Intervention Trial Research Group.
    Geriatr Gerontol Int; 2012 Apr 20; 12 Suppl 1():88-102. PubMed ID: 22435944
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
    Goldstein LB, Amarenco P, Lamonte M, Gilbert S, Messig M, Callahan A, Hennerici M, Sillesen H, Welch KM, SPARCL Investigators.
    Stroke; 2008 Sep 20; 39(9):2444-8. PubMed ID: 18617654
    [Abstract] [Full Text] [Related]

  • 18. Utility of Framingham Coronary Heart Disease Risk Score for predicting cardiac risk after stroke.
    Towfighi A, Markovic D, Ovbiagele B.
    Stroke; 2012 Nov 20; 43(11):2942-7. PubMed ID: 22949478
    [Abstract] [Full Text] [Related]

  • 19. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL).
    Arsenault BJ, Boekholdt SM, Mora S, DeMicco DA, Bao W, Tardif JC, Amarenco P, Pedersen T, Barter P, Waters DD.
    Am J Cardiol; 2014 Apr 15; 113(8):1378-82. PubMed ID: 24582532
    [Abstract] [Full Text] [Related]

  • 20. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E.
    J Am Coll Cardiol; 2008 Sep 09; 52(11):914-20. PubMed ID: 18772061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.